Compare Genuine Parts Company (GPC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs BIO-TECHNE Corp — how do they compare? Genuine Parts Company trades at $127.56 (market cap $17.29B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Genuine Parts Company is the larger of the two by market cap, and Genuine Parts Company pays the higher dividend (3.39%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and BIO-TECHNE Corp for 63 Days on average.
| GPC | TECH | |
|---|---|---|
Market Cap | $17.29B | $11.37B |
Volume | 900,870 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $72.61 |
52-Week Low | $92.47 | $43.31 |
Typical Hold Time | 75 Days | 63 Days |
Enterprise Value | $23.38B | $11.40B |
Dividend Yield | 3.39% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $128.17, up 0.62% today, with a bearish technical signal but neutral oscillators. The company reported mixed earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a Buy with a $145.75 price target, and the upcoming spinoff of the industrial unit Motion in Q1 2027 is a key catalyst.
The outlook is cautiously optimistic due to the spinoff potential and dividend stability, but risks include declining profitability, high P/E ratio of 501.64, and bearish technical trends. Investors should weigh the long-term benefits of the separation against near-term margin pressures and debt levels rising to 23.08% of assets in 2025.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
